CME Group Reports Record International Average Daily Volume of 9.2 Million Contracts in Q2 2025, Marking 18% Year-Over-Year Growth

Reuters
2025/07/10
CME Group Reports Record International Average Daily Volume of 9.2 Million Contracts in <a href="https://laohu8.com/S/QTWO">Q2</a> 2025, Marking 18% Year-Over-Year Growth

CME Group Inc., the world's leading derivatives marketplace, reported a record international average daily volume $(ADV)$ of 9.2 million contracts for the second quarter of 2025, marking an 18% increase compared to the previous year. The growth in volume was primarily driven by record performances in the Europe, Middle East, and Africa (EMEA) region, with an ADV of 6.7 million contracts, up 15%, and the Asia Pacific (APAC) region, with an ADV of 2.2 million contracts, up 30%. In EMEA, the rise was supported by significant increases in Equity Index products, up 43%, Energy products, up 15%, Interest Rate products, up 12%, and Metals products, up 5%. Meanwhile, in APAC, the surge was attributed to a 67% increase in Energy products, a 34% rise in Metals, and a 13% growth in Agricultural products. Julie Winkler, Senior Managing Director and Chief Commercial Officer at CME Group, noted that the organization's comprehensive global benchmarks and liquidity have played a crucial role in enabling clients to manage risk effectively amidst heightened market volatility.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CME Group Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: AQ27093) on July 10, 2025, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10